Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Brain Cancer - Pipeline Review, H1 2012: New research report available at Fast Market Research


Print article Print article
2012-02-09 09:57:07 - Recently published research from Global Markets Direct, "Brain Cancer - Pipeline Review, H1 2012", is now available at Fast Market Research

Brain Cancer - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Brain Cancer - Pipeline Review, H1 2012', provides an overview of the Brain Cancer therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. 'Brain Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/330092_brain_cancer_pipeline_review_h1_2012. ..


Scope

* A snapshot of the global therapeutic scenario for Brain Cancer.
* A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Brain Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Brain Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Brain Cancer
Brain Cancer Therapeutics under Development by Companies
Brain Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Brain Cancer Therapeutics - Products under Development by Companies
Brain Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Brain Cancer Therapeutics Development
Abbott Laboratories
United Therapeutics Corporation
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Alkermes, Inc.
YM BioSciences Inc.
Aposense Ltd.
Advocate Health Care
Novartis AG
Dong-A Pharmaceutical Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Celgene Corporation
Geron Corporation
Advaxis, Inc.
4SC AG
GW Pharmaceuticals plc
Bionomics Limited
Peregrine Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
TopoTarget A/S
Mundipharma International Limited
Protox Therapeutics Inc.
e-Therapeutics plc
Morphotek, Inc.
Spectrum Pharmaceuticals, Inc.
Ambit Biosciences Corporation
Philogen S.p.A.
BioNumerik Pharmaceuticals, Inc.
Oncolin Therapeutics, Inc.
Pervasis Therapeutics, Inc.
Nobelpharma Co., Ltd.
Stemline Therapeutics, Inc.
BiPar Sciences, Inc.
Globeimmune, Inc.
Kinex Pharmaceuticals, LLC
to-BBB technologies BV
Archer Biosciences, Inc
Advanced Cancer Therapeutics
VectorLogics, Inc.
Brain Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Hycamtin + Whole Brain Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herceptin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TransMID - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
memantine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide phosphate + Ifosfamide + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330092&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser